CYRX - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by. This is the conference operator. Welcome to the Cryoport Inc. Full Year 2019 Earnings Conference Call.

As a reminder, all participants are in listen-only mode and the conference is being recorded. will opportunity there ask presentation, the be to an questions. After Instructions] [Operator

now I the the conference Managing to over turn KCSA. would go like Please to ahead. Partner, Todd Fromer,

Todd Fromer

Thank you, operator.

and that would All future statements. that are and in forward-looking to we address assumptions events These to I expect certain performance, statements today, statements operating forward-looking on developments management begin call contains our statements. information we remind Before management's on are the everyone currently or this our or conference forward-looking occurring beliefs like not based that anticipate available team.

these statements believes team management when and reasonable made. Our forward-looking are as

undertake should not update or obligation any you as except such speak future to forward-looking on any revise only by a otherwise, as or statements, information, forward-looking as not statements, of new the However, required made. result law. any undue such events when of statements place publicly because date whether reliance do We

forward-looking actual risks In from experience XA addition, with on the in those Securities and to expectations the filed risk elsewhere that described Commission. annual time and but differ risks and uncertainties to are our to events report from or our include, developments described results, Item could limited not materially historical those and Exchange our and reports, present other Form we certain which to uncertainties in and These and with projections. filed statements and are XX-K factors Securities Commission time subject cause in Exchange

of the yours. floor Cryoport. Shelton, like Mr. Executive I Officer Jerrell is turn to to the over now would call Jerry, Chief

Jerrell Shelton

Chief Stefanovich; Thank Mr. me today. our afternoon you, Chief Dr. Financial our Good Sawicki. this gentlemen. Robert you joining for us ladies Commercial Mark With Thank Todd. afternoon, is Officer, and Officer, and

our our financial provides the Presentations. performance uploaded review and review under and of a It be website. can Relations outlook. we to year-end recent Investor a and This found a reminder, document in general document business our have section XXXX As Events operational

read it, you and So if have to you encourage download not to website would go I it. chance to a had the

on the address will provide general to results where call, As you question-and-answer we with move update conference with queries brief session after then and regarding we'll our will previous quarters, a update. your the company's we this

reported with the the during an from year bluebird XXXX XXX% We $X.X include launch revenues XXXX. is the of compared fiscal first Revenue which XXXX. will result in from year revenue increase increase YESCARTA was Novartis' of KYMRIAH, to quarter agreements XX% prior commercial record million our continue of year. million, driven fiscal Gilead's $XX.X strong an ZYNTEGLO, our by for This contributed bio's of million partly agreements $X.X throughout XX-month or commercial period, of supporting to from and expected and the grow commercial XXXX, commencing

A record of were Licensing and filed total of during quarter Applications five Cryoport Biologic fourth supported Marketing XXXX. Authorization the Applications

BLA’s the internal We XX in Regenerative MAA’s forecasts expect from supported on filed additional based XXXX, for Medicine. and to information Alliance approximately be Cryoport and

clinical and gene new increased, of regenerative trials and with As the our market. share secured global therapies expanded number medicine cell and clients market we the

compared supported fourth are currently XX of the end at XX regenerative Phase the which of with which to total of bringing total our of trials added in by During III. XXX number clinical trials a XXXX XXX record we clinical were therapy quarter, of a XX trials in Phase net III Cryoport

all equipment, product has by provides use for advanced enhancing each XX.XXXX% year therapy the of biostorage our with to with commodities. human we only which the first position been of entering and platform invested guarantees Express, components ever the in further line, effectiveness leadership acquisition shipper advance and launching During disclaimed Cryogene shipper the market our complete and used traceability Cryoport

As these clients differentiated logistics solutions last an include expanded now of critical and year, temperature-controlled both we're global that a result our of with platform highly biostorage investments providing services.

and With Ecosystem the developing life Regenerative industry. Medicine within market a processes of systems partners, the the Unified Compliance support that Cryoport rapidly, growing sciences is network

Lonza, Chain In global XXXX, We sciences standardized we for are and secured top-tier compliance including successfully continuing further by industry on life focused chain of solutions advanced solutions have through several of chain supply into Global platform partnerships Morris therapies the New network other Texas. of providing Jersey Vineti, regenerative Plains, life including EVERSANA sciences and to Supply supply expand scalable, Centers our in build-out Houston, and integrating and the therapies.

We positioned balance organic acquisitive us believe growth. continued and strong business that sheet well has model Cryoport's for both

our market of continues superior the support us operations ecosystem position and global to our rapid as ability market platforms and leading scale to expand to the give and the Regenerative technology Our accelerating Medicine also growth. demonstrate

the call Now to to open answers. lines I'll our and questions over turn operator the for telephone your the

Operator

question from with Couillard Jefferies. comes Please first ahead. go Thank you. Our Brandon [Operator Instructions]

Unidentified Analyst

on Thanks Matt taking the for is Brandon. questions. This for

we you reconcile if revenues the non-commercial -- from laid the you look the versus then the trials as growth and that trials across though trend essentially you more It's XX timing ranges simply bands the in than relevant added the half to half in historically clinical your have biopharma of is clinical a or various the by of year, trial one, clinical First ballpark as versus issues clinical revenue the in the three phases? just trials or follow-up even support clinical ongoing new their out Thanks. still ramp second transition phase of phases. year And half. first today? help at first the flat trial the us revenues, Can of the

Jerrell Shelton

I'm Sawicki all to turn to answer that It's answer question. in going that Yes. your over Mark to but the

Mark Sawicki

Yes. Thanks.

basis more interruptions trials have in five or commercial which obviously And due associated volatility part that the a has earnings progression associated volatility. we trial outlined given line terminations which So with pipeline the for program release. revenue clinical basis as clinical on ultimately of associated as to bottom be lack activity and we revenue between dose heritage trials, clinical part use in the in of revenues with hold can units cycle in

Unidentified Analyst

Thanks. kind Bioservices the that there. Curious to base penciling provide from of you side, any recently it synergies platform. you customer just in their made customers? to offering terms several cross-selling the that's of initial And for feedback, And existing Cryogen then can your your what you're with know if clients progress then onboarded XXXX you revenue is Cryogene? some on resonating anything about And in

Jerrell Shelton

to that want Mark? take you Do

Mark Sawicki

Sure.

And a that that in acquisition one businesses behind an So is year. that this yes, supply we're The will do is actually of primary -- reasons forward folks last we we which fiscal supplier believe accelerate year. integrated crossover unique single primary move chain. between the towards or with seeing driver moving the

to storage. So platform, only logistics able but chain want they to be support not supply also distribution our the through aspects

Unidentified Analyst

Thanks. Super.

Operator

with next please. Puneet Souda SVB Go from comes Leerink. The question ahead

Puneet Souda

Yes. Hi, guys. Thanks.

that is was unclear to one you revenue first dynamic if provide how I revenue wanted quarter? shaping ASP of stepping Can is in Jerry up both and therapies for that on first there too. why was driven? maybe up. other down some wanted understand the were into understand how here commercial So Mark and you when just maybe we're commercial can – to Or much that in chime it for the

Jerrell Shelton

program is are or or second line into divided Puneet. for patient that we revenues. custom good two secondary a for us validations One ensuing got report commercial And customers services good is packaging example, you revenues The these thing. consulting categories. where management question our category sort primary of Yes, related the ask business or

a from of a So in the the services the drop revenue a fourth of revenue dropping. there quarter as of quarter third bit was related non-shipping result

Puneet Souda

here would recover that And that it Or something revenue? expectation the Or should year? that to first decline you your on quarter? the what's expect we again through expect to in is

Jerrell Shelton

drop in a office constantly constant – a No. But areas. last an need is in that in This its had activity evolving. flow. there's This just always space. quarter. It There's It's these here. a

it's going just continue numbers so to Yes. will its mean – it's yes, to – rebound. the develop. And I

Puneet Souda

repeat? you Sorry I that. didn't catch Can

Jerrell Shelton

rebound. said numbers I will the Yes

Puneet Souda

Okay.

Jerrell Shelton

Mark is different thing I way. in said said the same a

said numbers. quarter just for – come simply Just a just drop we had those a a we numbers will back. the in If had

Puneet Souda

but of sense or Okay. any were that saw All the clinical understand I a But trials trials on trials to you're get year sort are wanted any far mean, And a high-volume there seeing on what you III the trials. XXXX getting I you bigger trials I recovery two question. I a that into on and these appreciate one-time for so in phenomena, in clinical view Phase then large have that. was you're right. that far quarter. other Thank that one-off phenomena were impacting so here

Jerrell Shelton

just will last to it. add explained. start Well, in have that have let as that influence we we Puneet Mark we we've And positive I'll and But do – quarter.

that population to anything especially being continuation, So you as clinical activity. both to I like – a don't we the would grows that? and add trials Mark commercial in anticipate

Mark Sawicki

on I Jerry activity. very overall we're bullish No the I mean, absolutely is clinical right. mean,

fourth alone. five have filed for quarter MAAs We BLAs or the

this there's XXXX. almost the raise activity XX tune space in $XX another expect We of the billion very year. to be in And filed very, financing aggressive

space So there's trial put a support that's of that the money continue will into the activity. lot being to clinical

Puneet Souda

are the shipping European how what is we're Okay. on among disruption the – market first coronavirus, from And question for far what think – the is expecting and quarter largely we last second shipments versus seeing what's then about for half? and note customers? logistics. the the that should And should or so of we Anything your given this half impact in given year any been your here the my seeing first you you are

Jerrell Shelton

certainly Puneet, virus. region. are any because our of so delayed impact, trials we most effective we're haven't But or XX seen of seeing APAC stopped significant the the Well any XXX not far in being region, the overly trial

stoppage We that see But we are novel don't at how have like unfolds. anyone any see or to point. this we delayed will this else

Puneet Souda

or locations? But any disruptions you in Europe any shipping other are logistics from and or Italy purposes expecting not

Jerrell Shelton

things months. I the how everything What what's everyone had point. is to be is don't tell subject we've going can't next unfold. impact the But up going to going happening you we're same We for Well can issues sure that the and tell I same to know over to to you else. this no

Mark Sawicki

Yes.

briefly. Let that me add just to

seen you strategy have and is management things feedback us one the we client in So asking pandemic essence. back coming for on our of

remarks have validated that fleeting the that down mentioned ability of is, unique things has in basically render that a opening equipment five reduction demonstrated cleaning One validated Jerry plants in protocol has Cryoport we coronavirus inactive. XX.XXXX% to our his that disinfects protocol to

it's where about So just grown us.

thing positive very a us. actually it's for So

Puneet Souda

Okay, got it. Thank you.

Operator

Janney from with next Knight Montgomery. Our comes Paul question

Paul Knight

talk industry, the while I of know therapies Can be Phase it's Jerry. factor. the seeing slower filings budget. have trial, seem slower the on the factors I to with going is Hi, Phase think growth are commercial side? number ramping clinical the the you academics you from that about industry I we're I in the on surprise Phase that limited What are the do on no

Jerrell Shelton

on is comment Well to a in the position actually epidemic. Paul, Mark better

to So you? I'm turning

Mark Sawicki

Yes.

So a Phase I the obviously Paul the market, these the therapies starting real into when to factor were they're situation. of move on Early into market. is going to maturation still move

is Now safety market Phase actually that data different is late-stage trial can the a themselves lot on interest starting to of target they immediately. Lorina for a the mature, move have follow-on into a II indication the of only studies

than demonstration think anything the the so or actually of I it's So maturation a else. of market

Paul Knight

expansion your Plains. Houston. in And And year kind do Houston to CapEx level? about you of do have then this then storage achieve you need and specifically, understand that I to talked in you What Morris more

there, it you could the will in But your it Plains what color be little global looks one will like what on just storage, it of center? vision? What a and be facility, Morris logistics a costs what

Jerrell Shelton

to global I'll moment. difference bioservices. these Yes. Robert explain These supply are what in let are. But centers, the the chain and logistics just me a centers center chain over financials turn centers global of the supply global in

in be will advanced operations year out rolled by offer will advanced addition this two investment logistics. fourth these our which our bioservices and network of will then global So the chain supply an to they be in quarter world-class

those processes. So the of tell Robert we're both can investment you that in making

Robert Stefanovich

Yes.

and Just on defined have past the we as our we investments logistics remember announced New that when set you Jersey clearly in executed those. centers

New Jersey, setting you supply centers the in at If we're chain and investments $X here where up phase at U.S. two million. this and look look million $X in global Houston next you between

solutions. global We kind logistics our And solutions well size-wise have a our plan XX,XXX those global clear and between as as of square for they'll around XX,XXX services provide foot.

Paul Knight

Thank Okay. you.

Operator

question comes Richard Capital ahead. next Our from Baldry Please Partners. go ROTH with

Richard Baldry

Thanks.

operating on will completions quarter? of Or the of Sort of year? following on those facilities with will in up coincident those the in fourth the of earlier be expected sort come cost the that, any

Jerrell Shelton

Robert?

Robert Stefanovich

Yes.

over they will QX. that see of setting we costs you'll couple up So building of obviously start as and will facilities and infrastructure quarters the the come go in online in the next

what you operational expect as center. global that's to cost So getting start the the sales only part of should -- costs supply chain of

Richard Baldry

look the they're quarter pretty I gross margins, in at the when revenue And despite actually some strong headwinds.

can you anything trends throughout as of talk would about we see XXXX? where one-time So Thanks. from, how those came playing there's oriented? strength sort Or revenue that out whether scales

Robert Stefanovich

XX% to able in XX%, solid really midst at Yes. margins. of mean, the the building of see you can't kind I right? because yet, XX%, gross point been we're out infrastructure, trends maintain We've this

not So that are one-time it's a There's margin QX. trend. events impacting not gross really in

Our still gross margin. stated XX% in is goal

Obviously, We're to supply next that in there year, if at the chain going we're time. point out not this look building at you get centers.

we you'll see increase. see we the we So facilities still in leveraging can have, to the that will the side as again, and gross some start margins. margin gross up Ultimately, down

Richard Baldry

XXXX, -- things but wouldn't for And, the some one-time OpEx little built again, as work and a the anything baseline and should a I stock has quarter some What throughout side around infrastructure been a work normalized the sort that fourth quarter is as quarters line? about it to there's in. bounced fourth the good you and there the top good Or give don't Is make baseline some one-time up understand a we guidance, others at is strong baseline? match to look bit you from scale of from, XXXX? had

Jerrell Shelton

out expenses. because think about XXXX operating continue, XXXX we're infrastructure, our capabilities. going in to out I XX% building we're had that if you its building we growth or compare It's now

you XXXX XXXX. and over see So operating will expenses an increase in

that, understand It's demand But very, these seeing. why in in the We're you clear of have chain us that's terms phases the industry. this to these revenue of in this of investments we're expectations up again, we're growth on supply market. our still And centers. early in building based making very we're that to setting

Richard Baldry

likelihood Okay. have people similarly to that Jerry, learned therapies two. will come that do commercializations to some sort to Last some in Is easier the Thanks. insights. first next industry do you commercially that might approved we would accelerate we done approvals, that, about the -- of, there the either How have have the would faster once you before? extent first how be, came when think that ramp, Or first of, commercial -- assuming be some were you the two the think are Sort watch because larger-scale do that ramp gauge ramp it approved? trials? how versus lessons

Jerrell Shelton

because exactly below to introduced Rich, right? Mark moment. it going the these Germany, going like, over companies going ramp to turn expect -- same, strategies, to they're different mean, I I'll the -- and it's in forth. don't have we latest to they So to so is be the Germany in But a first. -- I'm to just different

but And to to we the Mark therapies, higher United don't as try that have the to so, look working opposed you the add so And as -- patient big expect really to as at population that. to States. just is will

Mark Sawicki

structures bottom these the Jerry are and right. line is of is I and The one is a variable of bedded lot is provide the standpoint. strategies have them unique. independent regulatory though how better that which the time, beneficial absolutely from to have mean, that been been that reimbursement guidance at over continues a which as commercialization with forward understanding the well a much mature, each the to cleaned FDA from manufacturing and up move will as

these of called, are guys of a of have, lot also point care. certified what And now set

patient them population. the so, using with to And them are the users to end introduce how understanding getting in comfortable

that these, the each looks what independent and them of will So those but they will are global population cadence I of basis the patient be them and a positive on how like. out on factors, think, impact overall roll

Richard Baldry

Thanks.

Operator

Our next Please with comes from question Johnson Stephens ahead. go Inc. Jacob

Mason Carrico

Jacob. have It's just actually a Mason on Hey, guys. question. for I two-part

Jerrell Shelton

you. hear can't we Jacob,

Mason Carrico

Can hear guys me? you

Jerrell Shelton

better, not bit little A but much.

Mason Carrico

right. All

about Sorry that.

So two-part is a this Mason have Jacob. I question. for on actually

shipping coming likely and to guidelines behavior are relates become change it once these could to as when guidance industry norm? methods? First happen standards be the to And regulation draft these the for how then second what And needs the for to they finalized. finalized

Jerrell Shelton

question. to That's Mark's great a And answer one. prepared that

Mark Sawicki

Yeah.

second of also one body regenerative ones So, the the through received around medicine, guidance or expectation that that folks The of document. coordinating of time. to Foundation our other working the with standards be for regulation We feedback expect bodies set this be Accreditation in and TC-XXX have XXXX the for would steering would requirements refinements receiving this submitted primary FDA year. by in regulatory been the is in ICO the Therapy, the guidance at It's the two from FDA point to be having which alliance early document and Cellular half to reviewed

believe that favorable compliance guidance will base systems our do very clients provide that to because platform compliance our our we processes systems. equipment in aspects construction, of in to We and be that its document, and – scrutiny and additional participating the management our and particular we're in distribution

So we're actually looking forward to it.

Mason Carrico

guys. you Thank it. Got

Mark Sawicki

My pleasure.

Operator

comes Please question Steve from ahead. next Needham. Unger with go Our

Steve Unger

Phase the early then in that new to this phases? phase across does these The it you number. come the an And new or had coming quarter? XXXX. Or numbers the a in in was on is in afternoon. impact that have in wins clients when clients the in presented comes the that big Good X? the if Or XX I Hi. – quarter, curious, And that's trial active are

Jerrell Shelton

turn over Mark question. to that That's I'm going Sawicki to a good

Mark Sawicki

Yeah.

So the that goals organization clients existing new and our either within start-ups have ,obviously an one is relationships the creditor clients of as to those as that And constitutes share well share market out capturing clinical been as of as for as the pull key traditionally. programs of can. we existing much relationships expansion using

So we're logistics compliance the we from increase is platform Honestly, of importance a points testament and can. I standpoint. rate our of folks to the very customer of those think as in active a that in factors capturing the acquisition traceability many distribution as understanding and that have we

point that's time. think given So clinical at associated around a that very biggest I this specific obviously timing is with to The identity of seeing in we're some the drivers those client. very,

Some of standpoint, a months others initiate done prior a the to not work clinical program. based pretrial six needs to them clinical initiating are already of shipping on from nine some consulting trial to activity and may negative get that for

Steve Unger

helpful. of clinical it. an That's XXXX. in the the have revenue quarter Lonza you then That's impact do was way Got characterizing sort And there outside Lonza if primarily understanding. trial And my you from is expect impact activity some in of the not, from relationship? of

Jerrell Shelton

won't announced relationship tell guidance had we've by that relationship And the impact nicely. during we or continuing in a announced for that the developing But is is on XXXX. with you last we struck an year special we this partnership especially Lonza we then giving special relationship Lonza. very state what be We And and can the several years.

commercial. for on Lonza that's actually and a for you started that's a to we going us. as strategic And of some basis as our impact well meet and see rollout comment But a to All are do regular other. may Mark have teams on

Mark Sawicki

already relationship that that. late revenue accretive year. think I'd of that obviously, that we add I early the XXXX. thing we XXX% But is relationship very benefit designing crossover associated development that are confident the the see on only we in with will other in of last It's, are seeing Yeah,

Steve Unger

on inception growth medicine expected layer wanted good the Got that it, to on a I accelerated impact than then had Is core and okay. you continue the reproductive to in the XXXX. growth fertility. is expectations It And What touch your to inception reproductive just win, growth? year fertility your for business.

Jerrell Shelton

It's a Steve. good question

focus the us. have hereto area. know -- for reproductive the And health. we plans first those our deal It's in big employed medicine But obviously before, bandwidth We're big. thing, really I and both in before EMEA, and that deal making of or reproductive further medicine. stated as to person to the for this have example, on is we We a through -- for push they investments didn't resources just big animal

And it I'll from let Mark probably. to it there and comment take on

Mark Sawicki

Yeah.

is Just in the as a network the United largest context, the prelude, States. network clinic inception

entire for parts signing that so substantial be deal, every our single event And their And on XXXX that we have do transportation believe moving obviously, forward. through IDF XXXX. in running will network that over prior a occurs numbers will upside

Steve Unger

much. Thank you very Great.

Operator

next Our with ahead. FBR. question Please D'Silva Andrew comes from Riley B. go

Andrew D’Silva

sorry question. you growth, what couple And it really where maybe to between growth touched do Street at -- you this, Thanks the where in Or is? years you XXXX? can look kind been on of biopharma of we XXXX? as of hopping think think in you is look me for you on relates rate saw saw elaborate reasonable XXXX? for the we expectation previous bit should a you let Frankly I just in calls. taking my And if a cadence have little know, any the directionally But a out as

Jerrell Shelton

through Andy bit -- heard assume to you're question And little we it didn't when that actually hear a fuzzy. coming we've your very don't well. Andrew I want

we you question, can So you your hear couldn't just restate well. very

Andrew D’Silva

better now? Can Absolutely. hear me you right

Jerrell Shelton

That's better. Yes.

Andrew D’Silva

Okay, good.

just about expect the about where a curious because that pretty place how shape would look be are on comfortable depending variances. how could over XXXX, I And a kind any consensus whole we of go we as significant effectively think there trajectory? was be year this they when similar growth you useful So was take XXXX on really is could cadence endpoints feel what we biopharma biopharma and several do should out color at really should

Jerrell Shelton

Mark. to to I'm turn Okay. that going

Mark Sawicki

Yeah.

on XX deli quarter in have of an But the at MMAs new BLA fact our one of launches clients. the at fourth well standpoint that from the quarter. XXXX filings as anticipate we are cadence on those the things five portfolio commercial for filed for of the -- timing alone five has the additional MAA looking as year that obviously impact we're Obviously for the we MAAs or XXXX. So this

-- which rollout So, what the at will those the we're cadence the bullish But impact ultimate looks very obviously, on the like. number year.

Andrew D'Silva

Okay.

Okay. offerings. Fair enough. touch expanding then And can on you maybe the just

You referenced if from that Cryoshuttle clients? I was there's -- before. highlight? on you any are can curious requests like things that success that like that through brought been date ideas being are offerings And if so if to

Jerrell Shelton

Well, and staying what I this year in think about look there both into bioservices. I cost we vertically. you acquisition made talked where said our and think last just if were We've of the are -- over expanding over about. And we Cryogene Cryoshuttle in about

We expect Cryoshuttle it's picking and on which it methodology while forth, to their to also expect and in things It Cryoshuttle have future. up is the takes the but the target. to get up so announced a of need and we picking is good and change grow people we and out validated that

-- consulting around word and our picking just we're recognize And growing. is that and because we've we up in certainly is and -- it's the authoritative consulting, field people getting in our

we're the expand to doing it's footprint. no proper product shipper, line therapy so, seen things -- then express that or the And in is one And expand not. you've it's usually has those kinds our the there's is advanced of industry revolutionary

disciplined So, a incremental as we're basis and very well. an basis removing on

Andrew D'Silva

about are about were XXX. I really accurate more question. throughout won't total involved net just Last Am the thinking increasing trials great. talk you're you talk or in assuming in some being generally ongoing sure trials, year-over-year. how just maybe year successful, fall We weren't many Can is XX. much you Okay, the involved trials I'm those in gain because off than that? I'm obviously

Jerrell Shelton

you're accurate Yes

Mark Sawicki

that. You don't take

Jerrell Shelton

that. Yes, in you're absolutely accurate

QX, I have an As was XX almost a quarter. example, net think but out XX, the of trials drop increase we over think there I

And that the terminations, front but So, the somewhere we adds in see. in range. net it to wasn't for XXs the in typical of have I that's prior don't was of so case numbers me, what

Andrew D'Silva

Okay.

So, fourth in macro quarters I to mean quarter that in market look the at revolving general or pushing had going process, previous was finished even anomaly through there kind things the grow you towards an I fallout than a the but a really continuing maybe when you're the lot just year. more think of getting in trends --

that you're indicative so and kind more frequency trend regenerative that of able more trend more to cell just grow, still that even the and -- And of and with just being -- is medicine market gene is that -- companies you before little maybe earlier related what therapy worked you importance underway? trials to clinical now offer? coming more companies really haven't bit Or of the a with or just or understanding

Jerrell Shelton

experimental is other be the It's in of It's this from it's us all nature nature. to volatile. its It's share clients clinical volatile our honest. pulling above to parties. And existing maturing, but trial in activity

is revenue commercialization events. of commercial that whole strategy share long-term capture around through Our drives

-- maintaining towards building they really commercialization. And on run so our this focused space we're through those relationships and our as in share

that end year. we and of last we're at the another filed starting And did BLAs/MAAs the year a this XX fruits to obviously see five of year the with

going eight theoretically to or from we supported or So, nine looking -- commercial two could be at in therapies by XXXX XX and XXXX. in

Andrew D'Silva

Okay, and great. Hey, thank you progress much. Congrats XXXX. in good very luck the on

Jerrell Shelton

much Andrew. very Thanks

Operator

to This over the I session. Jerrell any conference like turn back remarks. Shelton would to for concludes the question-and-answer closing

Jerrell Shelton

you, Thank operator.

Operator

call. concludes today's conference This

disconnect day. You lines. for have and may a pleasant participating Thank your you

Cryoport (CYRX) 5 Mar 202019 Q4 Earnings call transcript